Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Ayala Pharmaceuticals (NASDAQ: AYLA) announced participation in two virtual investor conferences in September 2021.

Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced participation in two virtual investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investor Conference will feature an on-demand corporate presentation available from September 13. Additionally, management will participate in meetings at Citi’s 16th Annual Biopharma Virtual Conference on September 9. Ayala focuses on developing small molecule therapeutics for rare and aggressive cancers, with two product candidates, AL101 and AL102, in advanced clinical trials targeting various cancers. More details can be found on their website.

Argus Session date unavailable

-0.61% session move Open Argus

Details

News Market Reaction – AYLA

The recorded move for AYLA in the trading session of this news was -0.61%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September:

• H.C. Wainwright 23^rd Annual Global Investor Conference: Corporate Presentation available on-demand starting Monday, September 13, 2021 at 7:00 am ET.
• Citi’s 16th Annual Biopharma Virtual Conference: Management will participate in investor meetings on Thursday, September 9, 2021.

A webcast of the H.C. Wainwright 23^rd Annual Global Investor Conference presentation may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the dates of Ayala Pharmaceuticals' investor conferences?

Ayala Pharmaceuticals will participate in Citi’s 16th Annual Biopharma Virtual Conference on September 9, 2021, and the H.C. Wainwright 23rd Annual Global Investor Conference starting September 13, 2021.

Where can I access the presentation from the H.C. Wainwright conference?

The H.C. Wainwright corporate presentation can be accessed on-demand at Ayala Pharmaceuticals' Events & Presentations section of their website from September 13, 2021.

What is the focus of Ayala Pharmaceuticals?

Ayala Pharmaceuticals is focused on developing and commercializing small molecule therapeutics for patients with rare and aggressive cancers.

What clinical trials is Ayala Pharmaceuticals currently conducting?

Ayala is conducting Phase 2 clinical trials for AL101 in patients with Adenoid Cystic Carcinoma and Triple Negative Breast Cancer and a Phase 2/3 trial for AL102 in patients with desmoid tumors.

What are the key product candidates of Ayala Pharmaceuticals?

Ayala Pharmaceuticals has two key product candidates: AL101 and AL102, targeting aberrant activation of the Notch pathway to treat various cancers.